Parkwoods Wealth Partners LLC Grows Stake in Eli Lilly and Company $LLY

Parkwoods Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 152.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,901 shares of the company’s stock after acquiring an additional 1,149 shares during the period. Eli Lilly and Company accounts for approximately 0.6% of Parkwoods Wealth Partners LLC’s investment portfolio, making the stock its 27th biggest holding. Parkwoods Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $2,043,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Exencial Wealth Advisors LLC lifted its position in Eli Lilly and Company by 189.6% in the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after acquiring an additional 11,396 shares during the last quarter. Rede Wealth LLC acquired a new position in Eli Lilly and Company in the third quarter valued at $487,000. Central Pacific Bank Trust Division grew its holdings in shares of Eli Lilly and Company by 25.8% during the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after purchasing an additional 1,843 shares during the last quarter. Cidel Asset Management Inc. increased its position in shares of Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock worth $20,392,000 after purchasing an additional 5,591 shares in the last quarter. Finally, Coldstream Capital Management Inc. increased its position in shares of Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock worth $32,365,000 after purchasing an additional 8,659 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on LLY. The Goldman Sachs Group set a $1,260.00 target price on Eli Lilly and Company in a research report on Thursday, February 5th. TD Cowen lifted their price target on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Morgan Stanley reiterated an “overweight” rating and issued a $1,313.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, March 5th. Bank of America increased their price objective on Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the company a “buy” rating in a report on Thursday. Finally, Jefferies Financial Group set a $1,300.00 target price on shares of Eli Lilly and Company and gave the company a “buy” rating in a report on Friday, March 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,222.22.

Eli Lilly and Company Stock Down 2.0%

LLY opened at $935.85 on Friday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The business has a 50 day moving average price of $996.24 and a two-hundred day moving average price of $966.65. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The company has a market cap of $884.21 billion, a PE ratio of 40.78, a P/E/G ratio of 1.11 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company’s revenue was up 42.6% on a year-over-year basis. During the same period last year, the business posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Lilly’s oral GLP‑1 weight‑loss pill Foundayo (orforglipron), enabling a commercial launch (via LillyDirect) and broader patient access—this is the main growth catalyst behind recent investor enthusiasm. FDA approves Lilly’s Foundayo (PR Newswire)
• Positive Sentiment: Bank of America and other sell‑side notes see Foundayo as a durable commercial opportunity (BofA called it a preferred oral GLP‑1); BofA also raised its price target and reiterated a Buy rating, supporting medium‑term analyst optimism. Bank of America sees Foundayo as preferred oral GLP-1
• Positive Sentiment: Street estimates see a multi‑billion dollar debut for Foundayo (analyst scenarios ~ $1.5B–$2.8B in 2026) and unusually large call‑option activity indicates speculative positioning for further upside from the drug launch. Foundayo Launch Could Drive Up to $2.8B (Blockonomi)
• Neutral Sentiment: Lilly agreed to acquire Centessa (deal value reported around $7.8B), diversifying Lilly’s pipeline into sleep/neuroscience — strategic for long‑term growth but adds near‑term integration and price‑premium risk. LLY to Buy Centessa Pharmaceuticals (Zacks)
• Negative Sentiment: Policy risk: the Trump administration is proposing steep tariffs on branded drugs for companies that haven’t struck pricing deals—this raises regulatory and margin uncertainty for big pharma, including Lilly. Trump Administration Unveils Up to 100% Tariff on Branded Drugs (WSJ)
• Negative Sentiment: Competitive/marketing noise: Novo Nordisk published cross‑trial comparisons claiming its oral Wegovy outperformed Foundayo, and media debate over efficacy/side‑effect differences is tempering some investor enthusiasm. Novo says Wegovy pill outperforms Lilly’s Foundayo (CNBC)

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.